From: Patterns and predictors of statin prescription in patients with type 2 diabetes
Characteristic | Primary prevention | Secondary prevention |
---|---|---|
Percent statin use | Percent statin use | |
Number | n = 27,322 18.5% | n = 17,571 38.1% |
Sex | ||
Male | 18.5% | 41.3% |
Female | 18.5% | 34.4% |
Age (years) | ||
<40 | 11.7% | 37.8% |
≥40 and <50 | 14.7% | 43.3% |
≥50 and <60 | 18.9% | 43.3% |
≥60 and <70 | 21.2% | 43.3% |
≥70 and <80 | 17.9% | 36.8% |
≥80 | 11.7% | 21.9% |
Age at diagnosis of diabetes (years) | ||
<45 | 16.6% | 44.8% |
≥45 and <55 | 19.0% | 42.1% |
≥55 and <65 | 20.5% | 41.0% |
≥65 | 16.4% | 31.8% |
Diabetes duration (years) | ||
<1 | 11.4% | 37.9% |
≥1 and <5 | 19.3% | 39.2% |
≥5 and <10 | 18.9% | 38.0% |
≥10 | 20.2% | 37.1% |
Body mass index (kg/m 2 ) | ||
<25 | 16.5% | 33.0% |
≥25 and <30 | 19.3% | 39.1% |
≥30 and <35 | 19.1% | 40.7% |
≥35 | 16.9% | 37.6% |
Smoking status | ||
Never smoker | 18.1% | 35.2% |
Former smoker | 20.1% | 44.8% |
Current smoker | 18.5% | 36.0% |
Hypertension | ||
no | 11.7% | 22.9% |
yes | 19.9% | 39.0% |
HbA1c (%) | ||
<6.5 | 17.8% | 36.9% |
≥6.5 and <7.5 | 19.2% | 39.8% |
≥7.5 and <8.5 | 18.8% | 36.7% |
≥8.5 | 17.6% | 38.5% |
Albuminuria | ||
No albuminuria | 17.4% | 37.4% |
Albuminuria (≥20 mg/l) | 19.0% | 39.1% |
Lipoprotein concentrations (mg/dl) | ||
Total cholesterol | ||
<200 | 19.9% | 47.2% |
≥200 and <240 | 16.2% | 34.8% |
≥240 | 19.7% | 32.6% |
LDL cholesterol | ||
<100 | 23.8% | 54.9% |
≥100 and <130 | 19.7% | 42.0% |
≥130 and <160 | 16.9% | 32.0% |
≥160 | 19.0% | 30.9% |
HDL cholesterol | ||
<40 (M) or <50 (F) | 19.9% | 38.2% |
≥40 (M) or ≥50 (F) | 19.1 | 39.9% |
Triglycerides | ||
<150 | 9.8% | 37.3% |
≥150 and <400 | 20.0% | 38.9% |
≥400 | 22.9% | 45.4% |
Estimated 5-year cardiovascular risk (%) | ||
<5 | 6.6% | |
≥5 and <10 | 13.9% | |
≥10 and <15 | 19.7% | |
≥15 and <20 | 23.4% | |
≥20 and <25 | 23.9% | |
≥25 and <30 | 26.9% | |
≥30 | 26.9% | |
Atherosclerotic complications | ||
Coronary heart disease | 40.1% | |
Cerebrovascular disease | 37.3% | |
Peripheral arterial occlusive disease | 38.0% |